Shopping Cart 0
Cart Subtotal
USD 0

Imugene Ltd (IMU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which researches and develops vaccines in the area of immune-oncology. The company focuses on developing immunotherapies for the treatment of HER-2+ gastric and breast cancer. The HER-2 receptor works on surface of various tumors including gastric, breast, ovarian and pancreatic cancers. Imugene's lead product candidate, HER-Vaxx is a HER-2+ cancer immunotherapy in Phase II clinical trials for the treatment of gastric cancer and completed Phase I clinical trials for the treatment of breast cancer. The company develops its vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes that recognized by an antibody with antitumor activity. Imugene is headquartered in Melbourne, Victoria, Australia.

Imugene Ltd (IMU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Imugene Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Imugene Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Imugene Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Imugene Enters into Agreement with Baker IDI Heart & Diabetes Institute 11

Imugene Enters Into Partnership with Medical University of Vienna 12

Imugene Enters into Agreement with Novotech 13

Licensing Agreements 14

Imugene Enters into Licensing Agreement with Ohio State University Wexner Medical Center and Mayo Clinic 14

Biolife Science Enters Into Licensing Agreement With Pevion Biotech For Virosomes Vaccine Delivery Platform 15

Equity Offering 16

Imugene to Raise USD6.2 Million in Rights Offering of Shares 16

Imugene to Raise up to USD9.2 Million in Private Placement of Shares 17

Imugene Raises USD1.6 Million in Rights Offering of Shares 18

Imugene Completes First Tranche Of Private Placement Of Shares For USD 0.76 Million 19

Imugene Completes Rights Offering Of Shares For USD 0.19 Million 20

Acquisition 21

Acuvax To Acquire Biolife Science, Maker Of Gastric And Breast Cancer Therapeutic Vaccines 21

Imugene Ltd-Key Competitors 22

Imugene Ltd-Key Employees 23

Imugene Ltd-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Corporate Communications 25

Oct 04, 2018: European Society for Medical Oncology President joins Imugene Scientific Advisory Board 25

Sep 18, 2018: Imugene names Tanios Bekaii-Saab to Scientific Advisory Board 26

Aug 23, 2018: Imugene names Dr Mark Marino Chief Medical Officer 27

Mar 28, 2018: Leslie Chong Appointed as Managing Director 28

Product News 29

Jul 23, 2018: Imugene: PD-1 cancer vaccine development update 29

02/12/2018: Novel Anti-PD-1 Mimotope Vaccine Ready for Development 30

Clinical Trials 31

Feb 13, 2017: Prestigious BMC Cancer journal publishes encouraging HER-Vaxx research 31

Other Significant Developments 33

Oct 30, 2018: Imugene: Business update-Appendix 4C for the quarter ended 33

Jul 31, 2018: Imugene: Business Update-Appendix 4C for the quarter ended 30 June 2018 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Imugene Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Imugene Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Imugene Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Imugene Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Imugene Enters into Agreement with Baker IDI Heart & Diabetes Institute 11

Imugene Enters Into Partnership with Medical University of Vienna 12

Imugene Enters into Agreement with Novotech 13

Imugene Enters into Licensing Agreement with Ohio State University Wexner Medical Center and Mayo Clinic 14

Biolife Science Enters Into Licensing Agreement With Pevion Biotech For Virosomes Vaccine Delivery Platform 15

Imugene to Raise USD6.2 Million in Rights Offering of Shares 16

Imugene to Raise up to USD9.2 Million in Private Placement of Shares 17

Imugene Raises USD1.6 Million in Rights Offering of Shares 18

Imugene Completes First Tranche Of Private Placement Of Shares For USD 0.76 Million 19

Imugene Completes Rights Offering Of Shares For USD 0.19 Million 20

Acuvax To Acquire Biolife Science, Maker Of Gastric And Breast Cancer Therapeutic Vaccines 21

Imugene Ltd, Key Competitors 22

Imugene Ltd, Key Employees 23

Imugene Ltd, Subsidiaries 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Imugene Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which researches and develops vaccines in the area of immune-oncology. The company focuses on developing immunotherapies for the treatment of HER-2+ gastric and breast cancer. The HER-2 receptor works on surface of various tumors including gastric, breast, ovarian and pancreatic cancers. Imugene's lead product candidate, HER-Vaxx is a HER-2+ cancer immunotherapy in Phase II clinical trials for the treatment of gastric cancer and completed Phase I clinical trials for the treatment of breast cancer. The company develops its vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes that recognized by an antibody with antitumor activity. Imugene is headquartered in Melbourne, Victoria, Australia.

Imugene Ltd (IMU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Imugene Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Imugene Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Imugene Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Imugene Enters into Agreement with Baker IDI Heart & Diabetes Institute 11

Imugene Enters Into Partnership with Medical University of Vienna 12

Imugene Enters into Agreement with Novotech 13

Licensing Agreements 14

Imugene Enters into Licensing Agreement with Ohio State University Wexner Medical Center and Mayo Clinic 14

Biolife Science Enters Into Licensing Agreement With Pevion Biotech For Virosomes Vaccine Delivery Platform 15

Equity Offering 16

Imugene to Raise USD6.2 Million in Rights Offering of Shares 16

Imugene to Raise up to USD9.2 Million in Private Placement of Shares 17

Imugene Raises USD1.6 Million in Rights Offering of Shares 18

Imugene Completes First Tranche Of Private Placement Of Shares For USD 0.76 Million 19

Imugene Completes Rights Offering Of Shares For USD 0.19 Million 20

Acquisition 21

Acuvax To Acquire Biolife Science, Maker Of Gastric And Breast Cancer Therapeutic Vaccines 21

Imugene Ltd-Key Competitors 22

Imugene Ltd-Key Employees 23

Imugene Ltd-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Corporate Communications 25

Oct 04, 2018: European Society for Medical Oncology President joins Imugene Scientific Advisory Board 25

Sep 18, 2018: Imugene names Tanios Bekaii-Saab to Scientific Advisory Board 26

Aug 23, 2018: Imugene names Dr Mark Marino Chief Medical Officer 27

Mar 28, 2018: Leslie Chong Appointed as Managing Director 28

Product News 29

Jul 23, 2018: Imugene: PD-1 cancer vaccine development update 29

02/12/2018: Novel Anti-PD-1 Mimotope Vaccine Ready for Development 30

Clinical Trials 31

Feb 13, 2017: Prestigious BMC Cancer journal publishes encouraging HER-Vaxx research 31

Other Significant Developments 33

Oct 30, 2018: Imugene: Business update-Appendix 4C for the quarter ended 33

Jul 31, 2018: Imugene: Business Update-Appendix 4C for the quarter ended 30 June 2018 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Imugene Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Imugene Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Imugene Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Imugene Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Imugene Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Imugene Enters into Agreement with Baker IDI Heart & Diabetes Institute 11

Imugene Enters Into Partnership with Medical University of Vienna 12

Imugene Enters into Agreement with Novotech 13

Imugene Enters into Licensing Agreement with Ohio State University Wexner Medical Center and Mayo Clinic 14

Biolife Science Enters Into Licensing Agreement With Pevion Biotech For Virosomes Vaccine Delivery Platform 15

Imugene to Raise USD6.2 Million in Rights Offering of Shares 16

Imugene to Raise up to USD9.2 Million in Private Placement of Shares 17

Imugene Raises USD1.6 Million in Rights Offering of Shares 18

Imugene Completes First Tranche Of Private Placement Of Shares For USD 0.76 Million 19

Imugene Completes Rights Offering Of Shares For USD 0.19 Million 20

Acuvax To Acquire Biolife Science, Maker Of Gastric And Breast Cancer Therapeutic Vaccines 21

Imugene Ltd, Key Competitors 22

Imugene Ltd, Key Employees 23

Imugene Ltd, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Imugene Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.